Aspen Neuroscience IPO 2026: Nasdaq ASPE, $347M Raised, and a Still-Blank Price Range

Aspen Neuroscience amended its IPO filing on October 22, 2026 to list on the Nasdaq Global Select Market under ticker ASPE, after raising about $347 million since 2018 from ARCH Venture Partners, OrbiMed, and other blue-chip biotech investors. The clinical-stage cell-therapy company's offering still has no price range or share count, leaving its targeted valuation unknown even as the deal nears pricing.

The San Diego-based biotech, incorporated in Delaware in 2018 and built on research from Scripps Research Institute's Jeanne F. Loring, is developing autologous cell therapies made from a patient's own reprogrammed stem cells. Its lead candidate, sasineprocel, targets Parkinson's disease and is dosing patients in the Phase 1/2a ASPIRO trial ahead of a planned Phase 3 study, according to the amended S-1 filed with the SEC.

Aspen Neuroscience IPO: Timeline From Series C to the Blank Price Range

Aspen's IPO filing has moved in stages since late 2025, growing its underwriting syndicate and firming up financial disclosures along the way, without yet setting the one number that matters most to public investors: a price.

How we counted: every milestone Aspen Neuroscience disclosed in its own SEC filings or that outlets reported directly from them; May 2018 through Oct 22, 2026; 6 milestones; as of October 22, 2026.

Why Aspen Neuroscience's Price Range Is Still Blank

Aspen's public S-1, filed October 9, 2026, placed a standard $100 million placeholder on the offering — a figure registrants use to calculate SEC filing fees, not a real estimate of deal size — with Leerink Partners, Piper Sandler, and Stifel as joint bookrunners, according to Renaissance Capital. By the October 22 amendment, the underwriting group had grown to five banks with the addition of UBS Investment Bank and Oppenheimer & Co., a sign the deal was progressing toward a roadshow — but the amendment still left the share price and count blank, meaning neither Aspen nor its bankers had settled on what the market should pay.

That gap matters for a company with Aspen's balance sheet: $72.4 million in cash against a $264.9 million accumulated deficit and a net loss that grew from $31.8 million in the first half of 2025 to $36.5 million in the first half of 2026, per the SEC filing. The company's own prospectus states there is "substantial doubt" about its ability to continue as a going concern on existing cash alone — language that makes this IPO less a growth-capital event than a runway extension the company needs to actually close.

How Does Aspen Neuroscience's Cell Therapy Work?

Sasineprocel (formerly ANPD001) is an autologous iPSC-derived cell therapy: it reprograms a patient's own skin cells into induced pluripotent stem cells, then differentiates those into dopamine-producing neurons that are transplanted back into the same patient's brain to treat Parkinson's disease. Using a patient's own cells sidesteps the immune-rejection risk that comes with donor-derived treatments, but it means every dose has to be custom-manufactured per patient rather than produced at scale from a single cell bank — the central bear case for the autologous category broadly, not specific to Aspen.

The therapy has dosed 15 patients as of an August 18, 2026 data cutoff in the open-label ASPIRO Phase 1/2a trial and holds RMAT and Fast Track designations from the FDA, according to the SEC filing. Aspen expects to begin dosing in a Phase 3 trial in the second half of 2027, per BioPharma Dive — meaning IPO proceeds are funding clinical risk on an unapproved therapy, not a near-term product launch.

What the headline misses

A growing underwriter syndicate is not a priced deal. Five banks on the cover page signals Aspen and its advisors are preparing for a roadshow, but it says nothing about what investors will actually pay — and biotech IPOs with blank price ranges this late in the process sometimes price below the issuer's hopes, or get pulled entirely, especially for a single-asset company still in Phase 1/2a trials with no approved product and a documented going-concern risk. Research and development already consumes more than 70% of Aspen's operating expenses, according to BioPharma Dive, so even a successful IPO funds one more leg of a long, expensive trial program rather than resolving the company's capital needs outright.